Anthrax Vaccines

Bacillus anthracis and Anthrax

Volumn , Issue , 2010, Pages 269-293

  Saile, Elke ^a   Quinn, Conrad P ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Anthrax vaccine duration, of induced immunity in humans initial priming series not known; Anthrax vaccine research, extensive data on PA vaccine efficacy, augmenting PA vaccine and employing novel delivery technologies and adjuvants; Anthrax vaccines, history of anthrax vaccines biomedical science, influenced by society's perception of threat posed by infectious diseases

Indexed keywords

EID: 84862586517     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470891193.ch14     Document Type: Chapter

References (188)

1. Abboud, N. and Casadevall, A. 2008. Immunogenicity of Bacillus anthracis protective antigen domains and effi-cacy of elicited antibody responses depend on host genetic background. Clin Vaccine Immunol, 15, 1115 - 1123.
2. Aloni-Grinstein, R., Gat, O., Altboum, Z., Velan, B., Cohen, S., and Shafferman, A. 2005. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun, 73, 4043 - 4053.
3. Auerbach, S. and Wright, G. G. 1955. Studies on immunity in anthrax. VI: Immunizing activity of protective antigen against various strains of Bacillus anthracis. J Immunol, 75, 129 - 133.
4. Aziz, M. A., Sikriwal, D., Singh, S., Jarugula, S., Kumar, P. A., and Bhatnagar, R. 2005. Transformation of an edible crop with the pag A gene of Bacillus anthracis. FASEB J, 19, 1501 - 1503.
5. Bail, O. 1904. Untersuchungen ueber nat ü rliche und k ü nstliche Milzbrandimmunit ä t. XI. Erster Bericht ueber Milzbrandschutzimpfungen an Schafen. Centralbl f Bakt, 37, 270 - 280.
6. Baillie, L., Hebdon, R., Flick-Smith, H., and Williamson, D. 2003. Characterisation of the immune response to the UK human anthrax vaccine. FEMS Immunol Med Microbiol, 36, 83 - 86.
7. Baillie, L. W., Rodriguez, A. L., Moore, S., Atkins, H. S., Feng, C., Nataro, J. P., and Pasetti, M. F. 2008. Towards a human oral vaccine for anthrax: the utility of a Salmonella typhi Ty21a-based prime-boost immunization strategy. Vaccine, 26, 6083 - 6091.
8. Bartkus, J. M. and Leppla, S. H. 1989. Transcriptional regulation of the protective antigen gene of Bacillus anthracis. Infect Immun, 57, 2295 - 2300.
9. Belton, F. C. and Henderson, D. W. 1956. A method for assaying anthrax immunising antigen and antibody. Br J Exp Pathol, 37, 156 - 160.
10. Belton, F. C. and Strange, R. E. 1954. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Br J Exp Pathol, 35, 144 - 152.
11. Bielinska, A. U., Janczak, K. W., Landers, J. J., Makidon, P., Sower, L. E., Peterson, J. W., and Baker, J. R., Jr. 2007. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun, 75, 4020 - 4029.
12. Blancou, J. M. 1974. Mixed vaccine against bacterial anthrax and symptomatic anthrax. Rev Elev Med Vet Pays Trop, 27, 183 - 187.
13. Boor, A. K. and Tresselt, H. B. 1955. An antigen prepared in vitro effective for immunization against anthrax. II: Concentration of the protective antigen by chemical fractionation. J Infect Dis, 97, 203 - 206.
14. Boyaka, P. N., Tafaro, A., Fischer, R., Leppla, S. H., Fujihashi, K., and Mcghee, J. R. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol, 170, 5636 - 5643.
15. Brachman, P. S. and Friedlander, A. 1999. MMWR Morb Mortal Wkly Rep, 50, 677 - 680.
16. Brachman, P. S., Gold, H., Plotkin, S. A., Fekety, F. R., Werrin, M., and Ingraham, N. R. 1962. Field evaluation of a human anthrax vaccine. Am J Public Health Nations Health, 52, 632 - 645.
17. Brahmbhatt, T. N., Darnell, S. C., Carvalho, H. M., Sanz, P., Kang, T. J., Bull, R. L., Rasmussen, S. B., Cross, A. S., and O ' Brien, A. D. 2007. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun, 75, 5240 - 5247.
18. Brossier, F., Levy, M., and Mock, M. 2002. Anthrax spores make an essential contribution to vaccine effi cacy. Infect Immun, 70, 661 - 664.
19. Cameron, J. 1969. The assay of the potency of anthrax spore vaccine. International Symposium on Biological Assay Methods of Vaccines and Sera. London, 1967. CDSC. 1982. Anthrax surveillance 1961 - 1980. Br Med J, 284, 204.
20. Chabot, D. J., Scorpio, A., Tobery, S. A., Little, S. F., Norris, S. L., Friedlander, A. M. 2004. Anthrax capsule vaccine protects against experimental infection. Vaccine, 23, 43 - 47.
21. Charlton, S., Herbert, M., Mcglashan, J., King, A., Jones, P., West, K., Roberts, A., Silman, N., Marks, T., Hudson, M., and Hallis, B. 2007. A study of the physiology of Bacillus anthracis Sterne during manufacture of the UK acellular anthrax vaccine. J Appl Microbiol, 103, 1453 - 1460.
22. Chawla, A., Midha, S., and Bhatnagar, R. 2009. Effi cacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys. Biotechnol J, 4, 391 - 399.
23. Cohen, S., Mendelson, I., Altboum, Z., Kobiler, D., Elhanany, E., Bino, T., Leitner, M., Inbar, I., Rosenberg, H., Gozes, Y., Barak, R., Fisher, M., Kronman, C., Velan, B., and Shafferman, A. 2000. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun, 68, 4549 - 4558.
24. Coulson, N. M., Fulop, M., and Titball, R. W. 1994. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine, 12, 1395 - 1401.
25. Cromartie, W. J., Watson, D. W., and Bloom, W. L. 1947. Studies of infection with Bacillus anthracis. II: The immunological and tissue damaging properties of extracts prepared from lesions of B. anthracis infection. J Infect Dis, 80, 14 - 27.
26. Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L., and Ahmed, R. 2003. Cutting edge: References 287 long-term B cell memory in humans after smallpox vaccination. J Immunol, 171, 4969 - 4973.
27. Darlow, H. M., Belton, F. C., and Henderson, D. W. 1956. The use of anthrax antigen to immunise man and monkey. Lancet, 271, 476 - 479.
28. Demicheli, V., Rivetti, D., Deeks, J. J., Jefferson, T., and Pratt, M. 1998. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine, 16, 880 - 16884.
29. Dubois, A. B., Freytag, L. C., and Clements, J. D. 2007. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine, 25, 4747 - 4754.
30. Duchars, M. 2007. Review of rPA anthrax vaccine clinical data. Minutes of the Food and Drug Administration Center for Biologics Evaluation and Research Workshop, Anthrax Vaccines: Bridging Correlates of Protection in Animals to Immunogenicity in Humans, November 8, Gaithersburg, MD.
31. Duchars, M., Gray, I., Lockett, A., and Curry, L. 2009. Safety, tolerability and immunogenicity of recombinant protective antigen (rPA) anthrax vaccine compared with anthrax vaccine adsorbed (AVA) in a healthy population. Proceedings of the 12th Annual Conference on Vaccine Research, April 27 - 29, Baltimore, MD.
32. Enstone, J. E., Wale, M. C., Nguyen-Van-Tam, J. S., and Pearson, J. C. 2003. Adverse medical events in British service personnel following anthrax vaccination. Vaccine, 21, 1348 - 1354.
33. Evans, A. S. and Brachman, P. S. 1991. Bacterial Infections of Humans: Epidemiology and Control, New York: Plenum Medical Book.
34. Ezzell, J. W., Ivins, B. E., and Leppla, S. H. 1984. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect Immun, 45, 761 - 767.
35. Ezzell, J. W., Mikesell, P., Ivins, B. E., and Leppla, S. H. 1985. In World ' s Debt to Pasteur, ed. H. Koprowski and S. A. Plotkin. New York: Alan R. Liss.
36. Fasanella, A., Tonello, F., Garofolo, G., Muraro, L., Carattoli, A., Adone, R., and Montecucco, C. 2008. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use. Vaccine, 26, 5684 - 5688.
37. FDA. 1985. Biological products; bacterial vaccines and toxoids; implementation of effi cacy review. Fed Regist, 50, 51002 - 51117.
38. FDA. 2005. Biological products; bacterial vaccines and toxoids; implementation of effi cacy review; anthrax vaccine adsorbed; fi nal order. Fed Regist, 70, 75180 - 75198.
39. Fee, E. and Brown, T. M. 2002. John Henry Bell: occupational anthrax pioneer. Am J Public Health, 92, 756 - 757.
40. Fellows, P. F., Linscott, M. K., Ivins, B. E., Pitt, M. L., Rossi, C. A., Gibbs, P. H., and Friedlander, A. M. 2001. Effi cacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine, 19, 3241 - 32417.
41. Flick-Smith, H. C., Eyles, J. E., Hebdon, R., Waters, E. L., Beedham, R. J., Stagg, T. J., Miller, J., Alpar, H. O., Baillie, L. W., and Williamson, E. D. 2002a. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun, 70, 2022 - 20228.
42. Flick-Smith, H. C., Walker, N. J., Gibson, P., Bullifent, H., Hayward, S., Miller, J., Titball, R. W., and Williamson, E. D. 2002b. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun, 70, 1653 - 1656.
43. Fritz, D. L., Jaax, N. K., Lawrence, W. B., Davis K. J., Pitt, M. L., Ezzell, J. W., and Friedlander, A. M. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest, 73, 691 - 702.
44. Galloway, D., Liner, A., Legutki, J., Mateczun, A., Barnewall, R., and ESTEP, J. 2004. Genetic immunization against anthrax. Vaccine, 22, 1604 - 1608.
45. Galloway, D. R. and Baillie, L. 2004. DNA vaccines against anthrax. Expert Opin Biol Ther, 4, 1661 - 1667. Garmory, H. S., Titball, R. W., Griffi n, K. F., Hahn, U., Bohm, R., and Beyer, W. 2003. Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect Immun, 71, 3831 - 3836.
46. Gaur, R., Gupta, P. K., Banerjea, A. C., and Singh, Y. 2002. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine, 20, 2836 - 2839.
47. Gauthier, Y. P., Tournier, J. N., Paucod, J. C., Corre, J. P., Mock, M., Goossens, P. L., and Vidal, D. R. 2009. Effi cacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect Immun, 77, 1197 - 1207.
48. Gladstone, G. P. 1946. Immunity to anthrax: protective antigen present in cell-free culture fi ltrates. Br J Exp Pathol, 27, 394 - 418.
49. Gladstone, G. P. 1948. Immunity to anthrax: production of the cell-free protective antigen in cellophane sacs. Br J Exp Pathol, 29, 379 - 389.
50. Gorse, G. J., Keitel, W., Keyserling, H., Taylor, D. N., Lock, M., Alves, K., Kenner, J., Deans, L., and Gurwith, M. 2006. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine, 24, 5950 - 5959.
51. Grabenstein, J. D. 2003. Anthrax vaccine: a review. Immunol Allergy Clin North Am, 23, 713 - 730. Grabenstein, J. D. 2008. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis, 46, 129 - 36.
52. Green, B. D., Battisti, L., Koehler, T. M., Thorne, C. B., and Ivins, B. E. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun, 49, 291 - 297.
53. Grunow, R., Porsch-Ozc ü r ü mez, M., Splettstoesser, W., Buckendahl, A., Hahn, U., Beyer, W., B ö hm, R., Huber, M., vd Esche, U., Bessler, W., Frangoulidis, D., and Finke, E. J. 2007. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Vaccine, 25, 3679 - 3683.
54. Gu, M., Hine, P. M., James Jackson, W., Giri, L., and Nabors, G. S. 2007. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine, 25, 526 - 534.
55. Gu, M. L., Leppla, S. H., and Klinman, D. M. 1999. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine, 17, 340 - 344.
56. Gubbins, M. J., Berry, J. D., Corbett, C. R., Mogridge, J., Yuan, X. Y., SchmidT, L., Nicolas, B., Kabani, A., and Tsang, R. S. 2006. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol, 47, 436 - 443.
57. Gubbins, M. J., Schmidt, L., Tsang, R. S., Berry, J. D., Kabani, A., and Stewart, D. I. 2007. Development of a competitive enzyme linked immunosorbent assay to identify epitope specifi c antibodies in recipients of the U.S. licensed anthrax vaccine. J Immunoassay Immunochem, 28, 213 - 225.
58. Hahn, U. K., Aichler, M., Boehm, R., and Beyer, W. 2006a. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine, 24, 4595 - 4597.
59. Hahn, U. K., Alex, M., Czerny, C. P., Bohm, R., and Beyer, W. 2004. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. Int J Med Microbiol, 294, 35 - 44.
60. Hahn, U. K., Boehm, R., and Beyer, W. 2006b. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine, 24, 4569 - 4571.
61. Hallis, B., Silman, N. J., Noonan, S., Baker, R., Roberts, A. D., Quinn, C. P., Marks, T., Wiblin, C., Lloyd, G., Robinson, A., and Hudson, M. J. 2002. Novel in vitro functional assays for the determination of anthrax toxin components. D ev Biol (Basel), 111, 321 - 326.
62. Hambleton, P., Carman, J. A., and Melling, J. 1984. Anthrax: the disease in relation to vaccines. Vaccine, 2, 125 - 132.
63. Hashimoto, M., Boyer, J. L., Hackett, N. R., Wilson, J. M., and Crystal, R. G. 2005. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun, 73, 6885 - 6891.
64. Hepburn, M. J., Hugh Dyson, E., Simpson, A. J., Brenneman, K. E., Bailey, N., Wilkinson, L., Hornby, R., Mateczun, A. J., Bell, M. G., and Baillie, L. W. 2007. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine, 25, 6089 - 6097.
65. Hermanson, G., Whitlow, V., Parker, S., Tonsky, K., Rusalov, D., Ferrari, M., Lalor, P., Komai, M., Mere, R., Bell, M., Brenneman, K., Mateczun, A., Evans, T., Kaslow, D., Galloway, D., and Hobart, P. 2004. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci U S A, 101, 13601 - 13606.
66. Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. F., Hauer, J., Mcdade, J., Osterholm, M. T., O ' toole, T., Parker, G., Perl, T. M., Russell, P. K., and Tonat, K. 1999. Anthrax as a biological weapon: medical and public health management. JAMA, 281, 1735 - 1745.
67. Ivins, B. E., Ezzell, J. W. Jr., Jemski, J., Hedlund, K. W., Ristroph, J. D., and Leppla, S. H. 1986. Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun, 52, 454 - 458.
68. Ivins, B. E., Fellows, P. F., and Nelson, G. O. 1994. Effi cacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine, 12, 872 - 874.
69. Ivins, B. E., Pitt, M. L., Fellows, P. F., Farchaus, J. W., Benner, G. E., Waag, D. M., Little, S. F., Anderson, G. W., Jr., Gibbs, P. H., and Friedlander, A. M. 1998. Comparative effi cacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine, 16, 1141 - 1148.
70. Ivins, B. E. and Welkos, S. L. 1988. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol, 4, 12 - 19.
71. Ivins, B. E., Welkos, S. L., Knudson, G. B., and Leblanc, D. J. 1988. Transposon Tn916 mutagenesis in Bacillus anthracis. Infect Immun, 56, 176 - 181.
72. Ivins, B. E., Welkos, S. L., Knudson, G. B., and Little, S. F. 1990. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect Immun, 58, 303 - 308.
73. Ivins, B. E., Welkos, S. L., Little, S. F., Crumrine, M. H., and Nelson, G. O. 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun, 60, 662 - 668.
74. Ivins, B. E., Welkos, S. L., Little, S. F., and Knudson, G. B. 1989. Cloned protective activity and progress in development of improved anthrax vaccines. Proceedings of the International Workshop on Anthrax. Winchester, England, Salisbury Medical Bulletin.
75. Jiang, G., Joshi, S. B., Peek, L. J., Brandau, D. T., Huang, J., Ferriter, M. S., Woodley, W. D., Ford, B. M., Mar, K. D., Mikszta, J. A., Hwang, C. R., Ulrich, R., Harvey, N. G., Middaugh, C. R., and Sullivan, V. J. 2006. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci, 95, 80 - 96.
76. Joellenbeck, L. M., Zwanziger, L. L., Durch, J. S., and Strom, B. S., eds. 2002. The Anthrax Vaccine. Is it Safe? Does it Work? Washington, DC: National Academy Press.
77. Johnson, A. D. and Spero, L. 1981. Comparison of growth and toxin production in two vaccine strains of Bacillus anthracis. Appl Environ Microbiol, 41, 1479 - 1481.
78. Jones, S. D. and Teigen, P. M. 2008. Anthrax in transit: practical experience and intellectual exchange. Isis, 99, 455 - 485.
79. Joyce, J., Cook, J., Chabot, D., Hepler, R., Shoop, W., Xu, Q., Stambaugh, T., Aste-Amezaga, M., Wang, S., Indrawati, L., Bruner, M., Friedlander, A., Keller, P., and Caulfi eld, M. 2006. Immunogenicity and protective effi cacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem, 281, 4831 - 4843.
80. Kelly, C. D., O ' loughlin, C., Gelder, F. B., Peterson, J. W., Sower, L. E., and Cirino, N. M. 2007. Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant. J Immune Based Ther Vaccines, 5, 11.
81. Kenney, R. T., Yu, J., Guebre-Xabier, M., Frech, S. A., Lambert, A., Heller, B. A., Ellingsworth, L. R., Eyles, J. E., Williamson, E. D., and Glenn, G. M. 2004. Induction of protective immunity against lethal anthrax challenge with a patch. J Infect Dis, 190, 774 - 782.
82. Kim, S. H., Park, S. A., Kim, H. K., Cho, Y. J., Kim, K. S., Kim, Y. H., Chun, J. H., and Lee, N. G. 2008. Enhancement of the immune responses of mice to Bacillus anthracis protective antigen by CIA07 combined with alum. Arch Pharm Res, 31, 1385 - 1392.
83. Kim, T. G., Galloway, D. R., and Langridge, W. H. 2004. Synthesis and assembly of anthrax lethal factor-cholera toxin B-subunit fusion protein in transgenic potato. Mol Biotechnol, 28, 175 - 183.
84. Klas, S. D., Petrie, C. R., Warwood, S. J., Williams, M. S., Olds, C. L., Stenz, J. P., Cheff, A. M., Hinchcliffe, M., Richardson, C., and Wimer, S. 2008. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine, 26, 5494 - 5502.
85. Klimpel, K. R., Molloy, S. S., Thomas, G., and Leppla, S. H. 1992. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specifi city and catalytic properties of furin. Proc Natl Acad Sci U S A, 89, 10277 - 10281.
86. Klinman, D. M. 2006. Adjuvant activity of CpG oligodeoxynucleotides. I nt Rev Immunol, 25, 135 - 154.
87. Klinman, D. M., Currie, D., Lee, G., Grippe, V., and Merkel, T. 2007. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect, 9, 1478 - 1483.
88. Klinman, D. M., Xie, H., and Ivins, B. E. 2006. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann N Y Acad Sci, 1082, 137 - 150.
89. Kolla, R. V., Chintalapati, S., Sabet, M., Santelli, E., Liddington, R. C., David, M., Fierer, J., Guiney, D., and Rickert, R. C. 2007. Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response. PLoS ONE, 2, e1044.
90. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., and Klinman, D. M. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374, 546 - 549.
91. Kubler-Kielb, J., Liu, T. Y., Mocca, C., Majadly, F., Robbins, J. B., and Schneerson, R. 2006. Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-D-glutamic acid-protein conjugates. Infect Immun, 74, 4744 - 4749.
92. Kubler-Kielb, J., Vinogradov, E., Hu, H., Leppla, S. H., Robbins, J. B., and Schneerson, R. 2008. Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component. Proceedings of the National Academy of Sciences, 105, 8709 - 8712.
93. Kwok, W. W., Yang, J., James, E., Bui, J., Huston, L., Wiesen, A. R., and Roti, M. 2008. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specifi c CD4 + T cells with a phenotype distinct from that of naive PA T cells. Infect Immun, 76, 4538 - 4545.
94. Laforce, M. F. 1978. Woolsorter ' s disease in England. Bull N Y Acad Med, 54, 956 - 963.
95. Lee, J. S., Groebner, J. L., Hadjipanayis, A. G., Negley, D. L., Schmaljohn, A. L., Welkos, S. L., Smith, L. A., and Smith, J. F. 2006. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine, 24, 6886 - 6892.
96. Leffel, E. K. and Pitt, L. M. 2005. Anthrax. In Biodefense: Research Methodology and Animal Models, ed. J. Swearengen. Danvers, MA: CRC Press.
97. Leoff, C., Saile, E., Rauvolfova, J., Quinn, C. P., Hoffmaster, A. R., Zhong, W., Mehta, A. S., Boons, G. J., Carlson, R. W., and Kannenberg, E. L. 2009. Secondary cell wall polysaccharides of Bacillus anthracis are antigens that contain specifi c epitopes which cross-react with three pathogenic Bacillus cereus strains that caused severe disease, and other epitopes common to all the Bacillus cereus strains tested. Glycobiology, 19, 665 - 673.
98. Li, Z. N., Mueller, S. N., Ye, L., Bu, Z., Yang, C., Ahmed, R., and Steinhauer, D. A. 2005. Chimeric infl uenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious infl uenza viruses, and antigenicity. J Virol, 79, 10003 - 10012.
99. Little, S. F., Ivins, B. E., Fellows, P. F., Pitt, M. L., Norris, S. L., and Andrews, G. P. 2004. Defi ning a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine, 22, 422 - 430.
100. Little, S. F. and Knudson, G. B. 1986. Comparative effi cacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun, 52, 509 - 512.
101. Luxembourg, A., Hannaman, D., Nolan, E., Ellefsen, B., Nakamura, G., Chau, L., Tellez, O., Little, S., and Bernard, R. 2008. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine, 26, 5216 - 5222.
102. Lyons, C. R., Lovchik, J., Hutt, J., Lipscomb, M. F., Wang, E., Heninger, S., Berliba, L., and Garrison, K. 2004. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect Immun, 72, 4801 - 4809.
103. Makino, S., Watarai, M., Cheun, H. I., Shirahata, T., and Uchida, I. 2002. Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax. J Infect Dis, 186, 227 - 233.
104. Manayani, D. J., Thomas, D., Dryden, K. A., Reddy, V., Siladi, M. E., Marlett, J. M., Rainey, G. J., Pique, M. E., Scobie, H. M., Yeager, M., Young, J. A., Manchester, M., and Schneemann, A. 2007. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS Pathog, 3, 1422 - 1431.
105. Marano, N., Plikaytis, B. D., Martin, S. W., Rose, C., Semenova, V. A., Martin, S. K., Freeman, A. E., Li, H., Mulligan, M. J., Parker, S. D., Babcock, J., Keitel, W., El sahly, H., Poland, G. A., Jacobson, R. M., Keyserling, H. L., Soroka, S. D., Fox, S. P., Stamper, J. L., Mcneil, M. M., Perkins, B. A., Messonnier, N., and Quinn, C. P. 2008. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA, 300, 1532 - 1543.
106. Marciani, D. J. 2003. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today, 8, 934 - 943.
107. Martin, B. L., Nelson, M. R., Labutta, R., King, T. E., Williams, J. F., Minor, M. C., Grabenstein, J. E., and Engler, R. J. M. 2002. Anthrax vaccine temporally associated systemic adverse events referred to a tertiary medical center. J Allergy Clin Immunol, 109, S145 - S145.
108. Matyas, G. R., Friedlander, A. M., Glenn, G. M., Little, S., Yu, J., and Alving, C. R. 2004. Needle-free skin patch vaccination method for anthrax. Infect Immun, 72, 1181 - 1183.
109. Mcbride, B. W., Mogg, A., Telfer, J. L., Lever, M. S., Miller, J., Turnbull, P. C., and Baillie, L. 1998. Protective effi cacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine, 16, 810 - 817.
110. Mckee, A. S., Munks, M. W., and Marrack, P. 2007. How do adjuvants work? Important considerations for new generation adjuvants. Immunity, 27, 687 - 690.
111. Mclachlan, J. B., Shelburne, C. P., Hart, J. P., Pizzo, S. V., Goyal, R., Brooking-Dixon, R., Staats, H. F., and Abraham, S. N. 2008. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med, 14, 536 - 541.
112. Mehta, A. S., Saile, E., Zhong, W., Buskas, T., Carlson, R., Kannenberg, E., Reed, Y., Quinn, C. P., and Boons, G. J. 2006. Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium. Chemistry, 12, 9136 - 9149.
113. Mendelson, I., Gat, O., Aloni-Grinstein, R., Altboum, Z., Inbar, I., Kronman, C., Bar-Haim, E., Cohen, S., Velan, B., and Shafferman, A. 2005. Effi cacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components. Vaccine, 23, 5688 - 5697.
114. Mikesell, P., Ivins, B. E., Ristroph, J. D., and Dreier, T. M. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun, 39, 371 - 376.
115. Mikszta, J. A., Sullivan, V. J., Dean, C., Waterston, A. M., Alarcon, J. B., Dekker, J. P., III, Brittingham, J. M., Huang, J., Hwang, C. R., Ferriter, M., Jiang, G., Mar, K., Saikh, K. U., Stiles, B. G., Roy, C. J., Ulrich, R. G., and Harvey, N. G. 2005. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis, 191, 278 - 288.
116. Mohamadzadeh, M., Duong, T., Hoover, T., and T. R. 2008. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria. Expert Rev Vaccines, 7, 163 - 174.
117. Mohamed, N., Clagett, M., Li, J., Jones, S., Pincus, S., D ' alia, G., Nardone, L., Babin, M., Spitalny, G., and Casey, L. 2005. A high-affi nity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. I nfect Immun, 73, 795 - 802.
118. Morefi eld, G. L., Tammariello, R. F., Purcell, B. K., Worsham, P. L., Chapman, J., Smith, L. A., Alarcon, J. B., Mikszta, J. A., and Ulrich, R. G. 2008. An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. J Immune Based Ther Vaccines, 6, 5.
119. Murphy, D., Dandeker, C., Horn, O., Hotopf, M., Hull, L., Jones, M., Marteau, T., Rona, R., and Wessely, S. 2006. UK armed forces responses to an informed consent policy for anthrax vaccination: a paradoxical effect? Vaccine, 24, 3109 - 3114.
120. Novak, J. M., Stein, M. P., Little, S. F., Leppla, S. H., and Friedlander, A. M. 1992. Functional characterization of protease-treated Bacillus anthracis protective antigen. J Biol Chem, 267, 17186 - 17193.
121. Park, Y. S., Lee, J. H., Hung, C. F., Wu, T. C., and Kim, T. W. 2008. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun, 76, 1952 - 1959.
122. Petosa, C., Collier, R. J., Klimpel, K. R., Leppla, S. H., and Liddington, R. C. 1997. Crystal structure of the anthrax toxin protective antigen. Nature, 385, 833 - 838.
123. Pezard, C., Weber, M., Sirard, J. C., Berche, P., and Mock, M. 1995. Protective immunity induced by Bacillus anthracis toxin- defi cient strains. Infect Immun, 63, 1369 - 1372.
124. Phipps, A. J., Premanandan, C., Barnewall, R. E., and Lairmore, M. D. 2004. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev, 68, 617 - 629.
125. Pitt, M. L., Little, S. F., Ivins, B. E., Fellows, P., Barth, J., Hewetson, J., Gibbs, P., Dertzbaugh, M., and Friedlander, A. M. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine, 19, 4768 - 4773.
126. Pittman, P. R. 2002. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine, 20 ( Suppl. 3 ), S48 - S50.
127. Pittman, P. R., Gibbs, P. H., Cannon, T. L., and Friedlander, A. M. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine, 20, 972 - 978.
128. Pittman, P. R., Kim-Ahn, G., Pifat, D. Y., Coonan, K., Gibbs, P., Little, S., Pace-Templeton, J. G., Myers, R., Parker, G. W., and Friedlander, A. M. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine, 20, 1412 - 1420.
129. Plotkin, S. A., Brachman, P. S., Utell, M., Bumford, F. H., and Atchison, M. M. 1960. An epidemic of inhalation anthrax, the fi rst in the twentieth century. I: Clinical features. Am J Med, 29, 992 - 1001.
130. Price, B. M., Liner, A. L., Park, S., Leppla, S. H., Mateczun, A. and Galloway, D. R. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun, 69, 4509 - 4515.
131. Puziss, M., Manning, L. C., Lynch, J. W., Barclaye, Abelow, I., and Wright, G. G. 1963. Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures. Appl Microbiol, 11, 330 - 334.
132. Puziss, M. and Wright, G. G. 1963. Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man. J Bacteriol, 85, 230 - 236.
133. Quesnel-Hellmann, A., Cleret, A., Vidal, D. R., and Tournier, J. N. 2006. Evidence for adjuvanticity of anthrax edema toxin. Vaccine, 24, 699 - 702.
134. Quinn, C. P., Dull, P. M., Semenova, V., Li, H., Crotty, S., Taylor, T. H., Steward-Clark, E., Stamey, K. L., Schmidt, D. S., Stinson, K. W., Freeman, A. E., Elie, C. M., Martin, S. K., Greene, C., Aubert, R. D., Glidewell, J., Perkins, B. A., Ahmed, R., and Stephens, D. S. 2004. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis, 190, 1228 - 1236.
135. Quinn, C. P., and Turnbull, P. C. B. 1998. Anthrax. London: Edward Arnold. Reuveny, S., White, M. D., Adar, Y. Y., Kafri, Y., Altboum, Z., Gozes, Y., Kobiler, D., Shafferman, A., and Velan, B. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun, 69, 2888 - 2893.
136. Rhie, G. E., Roehrl, M. H., Mourez, M., Collier, R. J., Mekalanos, J. J., and Wang, J. Y. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci U S A, 100, 10925 - 10930.
137. Rijpkema, S. G., Adams, T., Rigsby, P., Xing, D. K., and Corbel, M. J. 2005. Investigation in a model system of the effects of combinations of anthrax and pertussis vaccines administered to service personnel in the 1991 Gulf War. Hum Vaccin, 1, 165 - 169.
138. Ross, J. M. 1957. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol, LXXIII, 485 - 494.
139. Rountree, P. M. 1983. Pasteur in Australia - Part II. Vaccination against anthrax. Australian Microbiologist, 4, 9 - 11.
140. Ruiz, W., Mcclements, W. L., Jansen, K. U., and Esser, M. T. 2005. Kinetics and isotype profi le of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines, 3, 2.
141. Russell, P. K. 2007. Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin Infect Dis, 45 ( Suppl. 1 ), S68 - S72.
142. Salsbery, C. E. 1926. Anthrax aggressin. J Am Vet Med Assn, 68, 755 - 772.
143. Sato, P., Ryan, M., and Gray, G. 2000. Surveillance for adverse events associated with anthrax vaccination - U.S. Department of Defense, 1998 - 2000. MMWR Morb Mortal Wkly Rep, 49, 341 - 345.
144. Schneerson, R., Kubler-Kielb, J., Liu, T. Y., Dai, Z. D., Leppla, S. H., Yergey, A., Backlund, P., Shiloach, J., Majadly, F., and Robbins, J. B. 2003. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci U S A, 100, 8945 - 8950.
145. Sellman, B. R., Mourez, M., and John Collier, R. 2001. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science, 292, 695 - 697.
146. Singh, Y., Klimpel, K. R., Arora, N., Sharma, M., and Leppla, S. H. 1994. The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J Biol Chem, 269, 29039 - 29046.
147. Sivasubramanian, A., Maynard, J. A., and Gray, J. J. 2008. Modeling the structure of mAb 14B7 bound to the anthrax protective antigen. Proteins, 70, 218 - 230.
148. Skoble, J., Beaber, J. W., Gao, Y., Lovchik, J. A., Sower, L. E., Liu, W., Luckett, W., Peterson, J. W., Calendar, R., Portnoy, D. A., Lyons, C. R., and Dubensky, T. W., Jr. 2009. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infect Immun, 77, 1649 - 1663.
149. Sloat, B. R. and Cui, Z. 2006. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res, 23, 1217 - 1226.
150. Smith, H. and Keppie, J. 1954. Observations on experimental anthrax; demonstration of a specifi c lethal factor produced in vivo by Bacillus anthracis. Nature, 173, 869 - 870. Sterne, M. 1937. Variation in Bacillus anthracis. Onderstepoort J Vet Sci Anim Ind, 8, 271 - 349.
151. Sterne, M. 1939. The use of saponin spore vaccine for inoculation against anthrax in South Africa. Ondersterpoort J Vet Sci Anim Ind, 12, 279 - 302.
152. Sterne, M. 1967. Distribution and economic importance of anthrax. Fed Proc, 26, 1493 - 1495.
153. Sterne, M., Nicol, J., and Lambrechts, M. 1942. The effect of large scale active immunization against anthrax. J S Afr Vet Med Assoc, 13, 53 - 63.
154. Sterne, M. and Robinson, E. M. 1939. The preparation of anthrax spore vaccines (for cattle and sheep) in South Africa. Onderstepoort J Vet Sci Anim Ind, 12, 9 - 18.
155. Stokes, M. G., Titball, R. W., Neeson, B. N., Galen, J. E., Walker, N. J., Stagg, A. J., Jenner, D. C., Thwaite, J. E., Nataro, J. P., Baillie, L. W., and Atkins, H. S. 2007. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun, 75, 1827 - 1834.
156. Swiderski, R. M. 2004. Anthrax: A History. Jefferson, NC: McFarland.
157. Tan, Y., Hackett, N. R., Boyer, J. L., and Crystal, R. G. 2003. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum Gene Ther, 14, 1673 - 1682.
158. Tigertt, W. D. 1980. Anthrax. William Smith Greenfi eld, MD FRCP. Concerning the priority due to him for the production of the fi rst vaccine against anthrax. J Hyg, 85, 415 - 420.
159. Tross, D. and Klinman, D. M. 2008. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J Immunol, 181, 5785 - 5790.
160. Turnbull, P. C. 1991. Anthrax vaccines: past, present and future. Vaccine, 9, 533 - 539.
161. Turnbull, P. C. 2000. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr Opin Infect Dis, 13, 113 - 120.
162. Turnbull, P. C. 2009. Anthrax vaccines. In Vaccines: A Biography, ed. A. W. Artenstein. New York: Springer.
163. Turnbull, P. C., Broster, M. G., Carman, J. A., Manchee, R. J., and Melling, J. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun, 52, 356 - 363.
164. Turnbull, P. C., Quinn, C. P., Hewson, R., Stockbridge, M. C., and Melling, J. 1990. Protection conferred by microbially supplemented UK and purifi ed PA vaccines. Proceedings of the International Workshop on Anthrax, April 11 - 13. Winchester, England, Salisbury Medical Bulletin (Special supplement).
165. Unwin, C., Blatchley, N., Coker, W., Ferry, S., Hotopf, M., Hull, L., Ismail, K., Palmer, I., David, A., and Wessely, S. 1999. Health of UK servicemen who served in Persian Gulf War. Lancet, 353, 169 - 178.
166. Vaccine against Anthrax. 1965. Br Med J, ii, 717 - 718.
167. Varughese, M., Teixeira, A. V., Liu, S., and Leppla, S. H. 1999. Identifi cation of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun, 67, 1860 - 1865.
168. Vasan, M., Rauvolfova, J., Wolfert, M. A., Leoff, C., Kannenberg, E. L., Quinn, C. P., Carlson, R. W., and Boons, G. J. 2008. Chemical synthesis and immunological properties of oligosaccharides derived from the vegetative cell wall of Bacillus anthracis. Chembiochem, 9, 1716 - 1720.
169. Vasconcelos, D., Barnewall, R., Babin, M., Hunt, R., Estep, J., Nielsen, C., Carnes, R., and Carney, J. 2003. Pathology of inhalation anthrax in cynomolgus monkeys ( Macaca fascicularis ). Lab Invest, 83, 1201 - 1209.
170. Wang, D., Carroll, G. T., Turro, N. J., Koberstein, J. T., Kovac, P., Saksena, R., Adamo, R., Herzenberg, L. A., and Steinman, L. 2007. Photogenerated glycan arrays identify immunogenic sugar moieties of Bacillus anthracis exosporium. Proteomics, 7, 180 - 184.
171. Wang, J. Y. and Roehrl, M. H. 2005. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med Immunol, 4, 4.
172. Wang, T. T., Fellows, P. F., Leighton, T. J., and Lucas, A. H. 2004. Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. F EMS Immunol Med Microbiol, 40, 231 - 237.
173. Watson, D. W., Cromartie, W. J., Bloom, W. L., Kegeles, G., and Heckly, R. J. 1947. Studies on infection with Bacillus anthracis. III: Chemical and immunological properties of the protective antigen in crude extracts of skin lesions of B. anthracis. J Infect Dis, 80, 28 - 40.
174. Watson, J., Koya, V., Leppla, S. H., and Daniell, H. 2004. Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop. Vaccine, 22, 4374 - 4384.
175. Welkos, S. L. and Friedlander, A. M. 1988a. Comparative safety and effi cacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog, 5, 127 - 139.
176. Welkos, S. L. and Friedlander, A. M. 1988b. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb Pathog, 4, 53 - 69.
177. Welkos, S. L., Lowe, J. R., Eden-Mccutchan, F., Vodkin, M., Leppla, S. H., and Schmidt, J. J. 1988. Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene, 69, 287 - 300.
178. Whitford, H. W. 1983. Anthrax: update and overview. Proc Am Assoc Vet Lab Diagn, 28, 1.
179. Williamson, E. D., Bennett, A. M., Perkins, S. D., Beedham, R. J., Miller, J., and Baillie, L. W. 2002. Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine, 20, 2933 - 2941.
180. Williamson, E. D., Hodgson, I., Walker, N. J., Topping, A. W., Duchars, M. G., Mott, J. M., Estep, J., Lebutt, C., Flick-Smith, H. C., Jones, H. E., Li, H., and Quinn, C. P. 2005. Immunogenicity of recombinant protective antigen and effi cacy against aerosol challenge with anthrax. Infect Immun, 73, 5978 - 5987.
181. Wimer-Mackin, S., Hinchcliffe, M., Petrie, C. R., Warwood, S. J., Tino, W. T., Williams, M. S., Stenz, J. P., Cheff, A., and Richardson, C. 2006. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine, 24, 3953 - 3963.
182. Wright, G. G., Green, T. W. and Kanode, R. G., Jr. 1954. Studies on immunity in anthrax. V: Immunizing activity of alum-precipitated protective antigen. J Immunol, 73, 387 - 391.
183. Wright, G. G., Puziss, M., and Neely, W. B. 1962. Studies on immunity in anthrax. IX: Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis. J Bacteriol, 83, 515 - 122.
184. Yan, M., Roehrl, M. H., Basar, E., and Wang, J. Y. 2008. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. Vaccine, 26, 947 - 955.
185. Zaucha, G. M., Pitt, L. M., Estep, J., Ivins, B. E., and Friedlander, A. M. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med, 122, 982 - 992.
186. Zegers, N. D., Kluter, E., Van Der Stap, H., Van Dura, E., Van Dalen, P., Shaw, M., and Baillie, L. 1999. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J Appl Microbiol, 87, 309 - 314.
187. Zeng, M., Xu, Q., and Pichichero, M. E. 2007. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Vaccine, 25, 3588 - 3594.
188. Zhang, Y., Martin, S. W., Rose, C. E., Jr., Biagini, R. E., Franzke, L. H., Smith, J. P., Sammons, D. L., Robertson, S. A., and Mcneil, M. M. 2008. Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women. Pharmacoepidemiol Drug Saf, 17, 1060 - 1067.